International Journal of Preventive Medicine (Int J Prev Med)2008-7802992018092219541954ENDepartment of Community Nutrition School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, TehranDepartment of Community Nutrition School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, TehranDepartment of Community Nutrition School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, TehranDepartment of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran20180922<p><span class="fontstyle0">Possible effects of coenzyme Q10 (CoQ10) supplement on the serum level of high-sensitivity C-reactive protein (hs-CRP) in cardiovascular diseases (CVDs) remains unclear. </span><span class="fontstyle2">Objective: </span><span class="fontstyle0">Therefore, this meta-analysis was conducted to investigate its effects on the serum hs-CRP level in patients with CVDs. A comprehensive search was conducted on the EMBASE, MEDLINE, and PubMed Central databases for pertinent papers in English up to November 2016. All randomized controlled trials (RCTs) that studied the effects of supplementation with CoQ10 on the serum of hs-CRP level in cardiovascular patients were included. We used random-effects models (the DerSimonian–Laird method) to estimate the pooled effect of selected studies and the </span><span class="fontstyle3">I</span><span class="fontstyle3" style="font-size: 5pt;">2 </span><span class="fontstyle0">test to assess the between-study heterogeneity. The subgroup analyses were carried out according to the baseline<br />serum hs-CRP, quality assessment score, supplementation dosage, and duration of intervention. Of 205 studies, five trials were eligible for inclusion in this study with 159 participants in the ntervention and 143 participants in the placebo group. Results of the pooled analysis revealed that the CoQ10 supplementation had no significant effect on the serum level of hs-CRP compared with the placebo group (MD: 0.120; 95% = -0.944, 1.185; </span><span class="fontstyle3">P </span><span class="fontstyle0">= 0.825). Moreover, the subgroup analyses showed the baseline serum hs-CRP, quality assessment score, and duration of intervention can be sources of heterogeneity. The results of this study demonstrated that the beneficial effect of CoQ10 supplementation for patients with CVDs is observed in those who received this supplement<br />for more than 12 weeks and with the baseline serum hs-CRP &gt;3 mg/L.<br /></span></p><p><span class="fontstyle2" style="color: #00652e;"><strong>Keywords</strong>: </span><span class="fontstyle3">Cardiovascular diseases, C-reactive protein, ubiquinone</span> </p>http://ijpm.mui.ac.ir/index.php/ijpm/article/view/1954http://ijpm.mui.ac.ir/index.php/ijpm/article/download/1954/717717773